This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Severe atopic dermatitis중증 아토피성 피부염

Contents and key points
ItemDetails
A. Classification codesICD-10: L20.85 | Special Copayment Reduction: V308 (severe intractable disease, 5 years)
B. Synonymssevere atopic dermatitis, severe atopic eczema
C. Adult onsetAdult onset high — atopic dermatitis commonly begins in childhood, but new onset in adulthood or recurrence after childhood improvement is also common. Severe adult atopic dermatitis follows a chronic course, and continuous treatment is often needed in the 20s–40s.
1. HistorySee main text
2. CausesSee main text
3. GeneticsSee main text
4. General epidemiologySee main text
5. PathophysiologySee main text
6. SymptomsSee main text
7. SignsSee main text
8. ScreeningSee main text
9. DiagnosisSee main text
10. TreatmentSee main text
11. PrognosisSee main text
12. PreventionSee main text
13. ReferencesSee main text

1. History

The history of atopic dermatitis (AD) goes back to antiquity, but the modern concept began in 1892 when Ernest Besnier first described it as prurigo diathésique. In 1923, Coca and Cooke introduced the term 'atopy' to name a group of diseases characterized by specific hypersensitivity reactions. In 1933, Sulzberger and Wise formally used the name 'atopic dermatitis', and the current disease name became established.

The history of treatment for severe atopic dermatitis reached a turning point in the mid-20th century with the introduction of corticosteroids. In 1952, Sulzberger and Witten reported the anti-inflammatory effect of topical hydrocortisone, and potent topical steroids subsequently became the mainstay of treatment for severe AD. However, as long-term steroid adverse effects (skin atrophy, steroid dependence) became a problem, calcineurin inhibitors (tacrolimus, pimecrolimus) were developed as an alternative in the 1990s.

The era of biologics opened in 2017 when dupilumab (an anti-IL-4Rα monoclonal antibody) received FDA approval for severe adult AD. Dupilumab suppresses Th2 inflammation by simultaneously blocking IL-4 and IL-13 signaling, and demonstrated groundbreaking efficacy in severe AD refractory to existing treatments. After 2022, tralokinumab (anti-IL-13), lebrikizumab (anti-IL-13), and JAK inhibitors (abrocitinib, upadacitinib) were additionally approved, further enriching treatment options for severe AD.


2. Causes

The cause of severe atopic dermatitis is understood as a complex interaction of genetic predisposition, environmental factors, skin barrier dysfunction, and immunological abnormalities.

Skin barrier abnormality

Variants of the filaggrin (FLG) gene are the most important genetic risk factor for severe AD. The FLG protein aggregates keratin filaments in the upper epidermis to maintain the structure of the stratum corneum and contributes to the production of natural moisturizing factor (NMF). FLG loss-of-function variants (R501X, 2282del4, etc.) reduce stratum corneum barrier function, increasing water loss and facilitating penetration of allergens and microorganisms into the skin.

Immunological abnormality

The immune response in severe AD is strongly Th2 (IL-4, IL-5, IL-13)-biased in the acute phase, and Th1, Th17, and Th22 responses are also mixed in the chronic phase. IL-4 and IL-13 promote IgE production in B cells and suppress expression of skin barrier proteins (FLG, claudins, etc.), causing a vicious cycle that further weakens barrier function. Epithelial cell-derived cytokines (alarmins) such as TSLP (thymic stromal lymphopoietin), IL-25, and IL-33 act as initiating signals of the Th2 response.

Environmental factors

Inhalant allergens such as house dust mites, pollen, and animal dander, food allergens (egg, milk, peanut, etc.), and Staphylococcus aureus skin colonization are exacerbating factors of severe AD. S. aureus secretes skin toxins (alpha toxin, delta toxin) and staphylococcal superantigens, which nonspecifically activate T cells and worsen skin inflammation. Air pollution, a Westernized lifestyle, the hygiene hypothesis, and reduced gut microbial diversity are also associated with the development of AD.


3. Genetics

The genetic basis of atopic dermatitis has been extensively explored through GWAS and candidate gene studies. Variants of the FLG gene (1q21.3) are the strongest genetic risk factor, and about 30–40% of AD patients of European ancestry carry FLG loss-of-function variants. In East Asians, the types of FLG variants differ somewhat; the R501X variant is uncommon in East Asia, and specific variants such as 7767delGT are reported.

HLA association: HLA-Cw*03:04 and HLA-DRB1*07:01 are associated with AD susceptibility in some studies. In particular, HLA-DRB1*07:01 is associated with a tendency toward IgE production and is being explored as a genetic background of the atopic march.

Immune-related genes: The Q576R variant of the IL-4Rα (IL4RA) gene is associated with amplification of IL-4 and IL-13 signaling and increases AD susceptibility. Polymorphisms of the IL-13, IL-31, TSLP, and TLSPR genes also contribute to AD susceptibility. Variants of the SPINK5 gene, which encodes a skin serine protease inhibitor (LEKTI), cause Netherton syndrome (severe ichthyosiform congenital exfoliative dermatitis).

Drug response genes: Associations between treatment response to tacrolimus and dupilumab and specific genotypes are being explored, and research toward a personalized treatment (precision medicine) approach is ongoing.


4. General epidemiology

Atopic dermatitis is one of the most common chronic skin diseases worldwide. Worldwide pediatric prevalence is about 10–20%, and adult prevalence is about 2–10%. In Korea, the prevalence of pediatric AD has risen sharply since the 1990s and is reported to reach about 20–30% in school-age children, and about 5–10% in adults.

Proportion of severe AD: About 10–20% of all AD patients are classified as moderate-to-severe. Severe AD, corresponding to EASI (Eczema Area and Severity Index) >21 or IGA (Investigator Global Assessment) 3–4, is often an indication for systemic treatment such as cyclosporine. In Korea, access to treatment for patients with severe AD improved greatly after dupilumab (covered since 2018).

Adult AD: Adult AD is divided into childhood-persistent and adult new-onset types. Adult new-onset AD accounts for about 25–30% of all AD and must be differentiated from occupational contact dermatitis and eczema related to dry skin. Severe adult AD markedly reduces quality of life (sleep disturbance, psychological distress, productivity loss), causing a disease burden comparable to psoriasis.


5. Pathophysiology

The pathophysiology of severe atopic dermatitis is explained as a vicious cycle in which three axes mutually reinforce one another: skin barrier dysfunction, aberrant immune response, and skin microbial change.

Skin barrier abnormality

When skin barrier function is reduced by FLG variants, abnormal stratum corneum lipid composition (decreased ceramides), and elevated stratum corneum pH, transepidermal water loss (TEWL) increases and allergens and microorganisms penetrate the skin more easily. Skin epithelial cells secrete TSLP, IL-25, and IL-33 in response to damage, and these alarmins activate Th2 cells, innate lymphoid cells (ILC2), and mast cells.

Amplification of the immune response

IL-4, IL-13, and IL-31 are secreted from activated Th2 cells. IL-4 promotes IgE class switching in B cells, and IL-13 suppresses expression of skin barrier proteins (FLG, loricrin, claudin-1), further worsening barrier function. IL-31 is a potent pruritus mediator and directly induces itch through IL-31R on sensory nerves. In chronic AD, Th1 (IFN-γ) and Th17 (IL-17) responses are also mixed, forming a complex inflammatory profile.

Skin microbial abnormality

In AD skin, Staphylococcus aureus colonization is markedly increased compared with healthy individuals. S. aureus secretes an IgE-binding protein (protein A), superantigens (TSST-1, enterotoxin B/C), skin toxins (α-toxin, delta-toxin), and a skin barrier-degrading protease (V8 protease), amplifying Th2 and Th17 inflammation and further worsening barrier function. Reduction of beneficial bacteria (especially Staphylococcus epidermidis) also lowers skin defense function.


6. Symptoms

The clinical symptoms of severe atopic dermatitis are characterized by extensive skin involvement, severe pruritus, sleep disturbance, and systemic symptoms.

Skin symptoms

Pruritus is the most prominent symptom, with intense itch that persists to the point of being 'impossible not to scratch'. Pruritus worsens at night and causes sleep disturbance. Skin lesions show a mixture of the acute phase (exudative erythema, blisters, crusts, exudate) and the chronic phase (lichenification, hyperpigmentation or hypopigmentation, dry scaling). In severe AD, EASI >21 or SCORAD >50, with lesions distributed over a wide area of the body surface.

Distribution characteristics

In adults, the flexural areas (inner elbows, behind the knees), neck, face, hands, and ankles are the main sites of involvement. In severe cases it spreads over the entire trunk and limbs. Periocular involvement requires caution because it raises the risk of cataract, uveitis, and keratoconus.

Quality of life and comorbidities

Severe AD is strongly associated with sleep disturbance, anxiety, depression, reduced concentration, and reduced occupational function. The Dermatology Life Quality Index (DLQI) score rises markedly to 10 or more in severe disease. Asthma, allergic rhinitis, food allergy, uveitis, eosinophilic esophagitis, and increased cardiovascular disease risk are known comorbid conditions.


7. Signs

On physical examination, extensive erythematous eruption, lichenified plaques, exudative lesions, and hyperkeratosis are observed, centered on the flexural areas, face, neck, and hands. Excoriation and crusts accompany. Atopy-associated findings include Dennie-Morgan lines: double folds of the lower eyelid; allergic shiner: darkening of the lower eyelid; keratosis pilaris, perioral pallor, and Hertoghe sign (loss of the lateral eyebrows).

On laboratory findings, serum elevated total IgE (often >2000 IU/mL), peripheral eosinophilia, and specific IgE (house dust mite, pollen, etc.) are confirmed. S. aureus colonization is detected at a high rate in skin lesion cultures. Severity is objectified with EASI, SCORAD, and IGA scores. Severe: EASI >21, SCORAD >50, IGA 3–4, DLQI >10.


8. Screening

Screening for severe adult AD is based on clinical symptoms. AD is suspected when early-onset eczematous lesions appear in infants and young children aged 2 months or older with a family history of atopy. AD is considered in adolescents and adults when pruritic eczematous lesions follow a chronic course on the flexural areas, face, and neck. For severity assessment, the EASI or SCORAD score, a quality-of-life index (DLQI), and a pruritus visual analog scale (VAS) are measured regularly. Serum total IgE and specific IgE panel testing and skin prick testing are used to assess allergen sensitization.


9. Diagnosis

Diagnosis of severe atopic dermatitis is mainly by clinical criteria. The Hanifin-Rajka criteria (1980) or the UK Working Party criteria are used internationally. Core criteria: pruritus, typical morphology and distribution (adults: flexural areas, face, neck), chronic or relapsing course, and personal or family history of atopy. ICD-10 L20.85 (severe) is used when clinical severity (EASI >21, SCORAD >50, IGA 3–4) is met. Differentiate from other eczematous skin diseases (contact dermatitis, seborrheic dermatitis, psoriasis, ichthyosis, mycosis fungoides, scabies, etc.). When necessary, skin biopsy (confirming epidermal hyperplasia, spongiosis, and chronic inflammatory cell infiltration in chronic lichenified lesions) and allergy patch testing are used to exclude contact allergens.


10. Treatment

Treatment of severe atopic dermatitis is based on the principles of stepwise approach (step-up therapy) and continuous maintenance management.

Topical treatment

Emollients are the basic treatment at all severity levels and should be applied generously at least twice daily to maintain the skin barrier. Topical corticosteroids (TCS) use medium-potency to potent preparations during acute flares, and long-term use is limited by adverse effects such as skin atrophy. Topical calcineurin inhibitors (TCI): tacrolimus 0.03% and 0.1% ointment and pimecrolimus 1% cream are used on sites vulnerable to steroid adverse effects, such as the face, neck, and flexural areas. Crisaborole (a PDE4 inhibitor) can be used as a steroid alternative in mild-to-moderate AD in patients aged 2 years and older.

Systemic treatment: biologics

Dupilumab is the first-line biologic for severe adult AD, targeting IL-4Rα to simultaneously block IL-4 and IL-13 signaling. It is administered by subcutaneous injection (300 mg every 2 weeks), and the EASI 75 (75% or greater improvement from baseline) achievement rate at 16 weeks is about 40–50%. National Health Insurance coverage was applied in Korea in 2018. Tralokinumab (anti-IL-13) and lebrikizumab (anti-IL-13) are additional biologics approved in 2022–2024.

Systemic treatment: JAK inhibitors

Abrocitinib (JAK1 inhibitor) and upadacitinib (preferential JAK1 inhibitor) are orally administered small-molecule targeted therapies available for severe AD. They show faster pruritus improvement than dupilumab, and monitoring for risk of thrombosis and malignancy is required.

Other systemic treatments

Cyclosporine (3–5 mg/kg/day), methotrexate (15–25 mg/week), azathioprine (2–3 mg/kg/day), and mycophenolate mofetil (1–3 g/day) were used before the introduction of biologics and are alternatives when dupilumab is ineffective or unavailable. Phototherapy (narrowband ultraviolet B, UVA1) is also effective in moderate-to-severe AD.


11. Prognosis

Severe atopic dermatitis is a chronic relapsing disease requiring long-term disease management. The prognosis of severe AD has improved markedly with the introduction of biologics, including dupilumab. With 16 weeks of dupilumab treatment, the EASI 75 achievement rate is 40–50%, and higher remission rates are reported with 52 weeks of maintenance. Studies show that JAK inhibitors (upadacitinib 30 mg) give even faster pruritus improvement and higher remission rates. However, about 30–40% of patients with severe AD show an inadequate response even to the latest treatments, so additional treatment options are needed. In severe AD, management of comorbid conditions such as psoriasis, depression, and cardiovascular disease affects prognosis. About 50–70% of children with severe AD improve in adulthood, but a substantial proportion persist as severe adult AD.


12. Prevention

Prevention strategies for severe atopic dermatitis center on strengthening skin barrier function, allergen avoidance, and minimizing pruritus triggers. Skin barrier strengthening: Studies suggest that early emollient use in infancy (at least twice daily) can lower the incidence of AD. The 'soak and seal' method of applying emollient immediately after a bath in warm water (30–32°C) is effective for maintaining barrier function. Allergen management: Avoiding house dust mites (mattress and pillow covers, weekly washing), avoiding pet dander, and caution during pollen season are helpful. Early allergen immunotherapy (sublingual immunotherapy, SLIT) is reported to reduce AD exacerbations in some patients. Prevention of skin infection: To reduce S. aureus colonization, diluted sodium hypochlorite baths (bleach baths), topical antimicrobial treatment (mupirocin), and skin hygiene management are performed. Maintenance of drug treatment: Continuous maintenance treatment with dupilumab or a JAK inhibitor is the most effective for preventing relapse.


13. References

  1. Weidinger S, Beck LA, Bieber T, et al. Atopic dermatitis. Nat Rev Dis Primers. 2018;4(1):1. DOI: 10.1038/s41572-018-0001-z.
  2. Simpson EL, Bieber T, Guttman-Yassky E, et al. Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. N Engl J Med. 2016;375(24):2335-2348. DOI: 10.1056/NEJMoa1610020.
  3. Guttman-Yassky E, Silverberg JI, Nemoto O, et al. Baricitinib in adult patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol. 2019;143(3):877-884. DOI: 10.1016/j.jaci.2018.01.018.
  4. Bieber T. Atopic Dermatitis: An Expanding Therapeutic Pipeline for a Complex Disease. Nat Rev Drug Discov. 2022;21(1):21-40. DOI: 10.1038/s41573-021-00266-6.
  5. Eichenfield LF, Tom WL, Chamlin SL, et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol. 2014;70(2):338-351. DOI: 10.1016/j.jaad.2013.10.010.
  6. Kim J, Kim BE, Leung DYM. Pathophysiology of atopic dermatitis: Clinical implications. Allergy Asthma Proc. 2019;40(2):84-92. DOI: 10.2500/aap.2019.40.4202.
  7. Barbarot S, Auziere S, Gadkari A, et al. Epidemiology of atopic dermatitis in adults: Results from an international survey. Allergy. 2018;73(6):1284-1293. DOI: 10.1111/all.13401.
  8. Ong PY, Leung DYM. Bacterial and viral infections in atopic dermatitis: a comprehensive review. Clin Rev Allergy Immunol. 2016;51(3):329-337.
  9. Wollenberg A, Christen-Zäch S, Taieb A, et al. ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. J Eur Acad Dermatol Venereol. 2020;34(12):2717-2744.
  10. Bae JM, Ha B, Lee H, et al. Prevalence of common skin diseases and their associated factors among military personnel in Korea. J Korean Med Sci. 2012;27(10):1248-1254.